Received: 16 November 2020
Accepted: 22 February 2021
First Online: 1 March 2021
: This study was approved by institutional review boards (Shinagawa East One Medical Clinic IRB, Adachi Kyosai Hospital IRB, Yokohama Minoru Clinic IRB, National Hospital Organization Tokushima Hospital IRB, Sone Clinic IRB) and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonization Good Clinical Practice Guidelines. All patients provided written informed consent before being enrolled in this study.
: Not applicable.
: YN received consulting fees from Seikagaku Corporation, during the conduct of the study; grants from Daiichi Sankyo Company, Limited, Novartis International AG, Pfizer Inc., Eisai Co., Ltd., Zimmer-Biomet, and Chugai Pharmaceutical Co., Ltd., consulting fees from Eli Lilly Japan K. K, lecture fees from Kaken Pharmaceutical Co. Ltd., Hisamitsu Pharmaceutical Co. Inc., Kyowa Kirin Co., Ltd., and Asahi Kasei Pharma Corporation, outside the submitted work. KK, TO, and TS are employees of Seikagaku Corporation.